Discounted Cash Flow (DCF) Analysis Levered
AVEO Pharmaceuticals, Inc. (AVEO)
$15
0.00 (0.00%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 7.58 | 5.41 | 28.79 | 6.02 | 38.87 | 123.47 | 392.17 | 1,245.61 | 3,956.31 | 12,566.01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -19.16 | -25.03 | -2.92 | -37.98 | -57.26 | -371.40 | -1,179.65 | -3,746.81 | -11,900.63 | -37,798.76 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | - | - | -0.36 | -2.34 | -7.45 | -23.65 | -75.12 | -238.60 | -757.84 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -19.16 | -25.03 | -2.92 | -38.35 | -59.60 | -378.85 | -1,203.31 | -3,821.94 | -12,139.23 | -38,556.60 |
Weighted Average Cost Of Capital
| Share price | $ 15 |
|---|---|
| Beta | 0.977 |
| Diluted Shares Outstanding | 21.40 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.255 |
| Total Debt | - |
| Total Equity | 321.03 |
| Total Capital | 321.03 |
| Debt Weighting | 0.00 |
| Equity Weighting | 100.00 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 7.58 | 5.41 | 28.79 | 6.02 | 38.87 | 123.47 | 392.17 | 1,245.61 | 3,956.31 | 12,566.01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.16 | -25.03 | -2.92 | -37.98 | -57.26 | -371.40 | -1,179.65 | -3,746.81 | -11,900.63 | -37,798.76 |
| Capital Expenditure | - | - | - | -0.36 | -2.34 | -7.45 | -23.65 | -75.12 | -238.60 | -757.84 |
| Free Cash Flow | -19.16 | -25.03 | -2.92 | -38.35 | -59.60 | -378.85 | -1,203.31 | -3,821.94 | -12,139.23 | -38,556.60 |
| WACC | ||||||||||
| PV LFCF | -349.95 | -1,026.69 | -3,012.17 | -8,837.29 | -25,927.38 | |||||
| SUM PV LFCF | -39,153.47 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 8.26 |
| Free cash flow (t + 1) | -39,327.73 |
| Terminal Value | -628,238.53 |
| Present Value of Terminal Value | -422,458.89 |
Intrinsic Value
| Enterprise Value | -461,612.36 |
|---|---|
| Net Debt | -70.54 |
| Equity Value | -461,541.82 |
| Shares Outstanding | 21.40 |
| Equity Value Per Share | -21,565.36 |